Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab.

Breast Cancer (Dove Med Press) · 2024 · PMC11135571 · PMID 38812479

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may not be significantno p-value reported

The median PFS of patients received pyrotinib as first-line vs second-line and higher regimens in this study was 16.7 months vs 10.5 months ( P =0.106), suggesting that the difference between the lines of pyrotinib treatment may not be significant.

also in 2,774 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.